Quantcast

Latest Vancomycin Stories

2011-05-10 07:45:00

SAN DIEGO, May 10, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the presentation of two abstracts at the 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) conference in Milan, Italy highlighting additional analyses of the Phase 3 data of DIFICID(TM) (fidaxomicin) for the treatment of Clostridium difficile infection (CDI). The data resulted from analysis of specific risk factors associated with negative outcomes in patients...

2011-05-09 12:00:00

CHICAGO, May 9, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the presentation of two abstracts at the 2011 Digestive Disease Week (DDW) conference highlighting additional analyses of data from Phase 3 trials of DIFICID(TM) (fidaxomicin), an investigational product for the treatment of Clostridium difficile infection (CDI). (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) The first analysis aimed to identify risk factors associated with...

2011-05-04 08:01:00

CLEVELAND, May 4, 2011 /PRNewswire/ -- Ganeden Biotech announced today that the company will present new in vivo data on the effect of its GanedenBC30 probiotic strain in C. diff infection at the Digestive Disease Week (DDW) conference in Chicago, Ill., from May 7-10, 2011. Jointly with its collaborator, Dr. Leo R. Fitzpatrick, Associate Professor from the Department of Pharmacology, Penn State College of Medicine, Pa., Ganeden will present data on the effect of GanedenBC30 on impacting C....

2011-04-28 07:00:00

SAN DIEGO, April 28, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced that additional data from the DIFICID(TM) Phase 3 trials will be presented at the following medical meetings: Digestive Disease Week (DDW), McCormick Place, Chicago, IL May 7-10, 2011 Poster Presentation Information: Risk of Recurrence and Time to Recurrence Following Title: Treatment of Clostridium difficile Infection:...

2011-04-27 10:00:00

EXTON, Pa., April 27, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the Deutsche Bank 36th Annual Healthcare Conference at 10:40 A.M. ET on Tuesday, May 3, 2011. The conference is being held at the InterContinental Hotel in Boston, MA. Vincent Milano, president and chief executive officer of ViroPharma, will present at the Bank of America/Merrill Lynch 2011...

2011-04-20 14:00:00

EXTON, Pa., April 20, 2011 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) first quarter financial results for 2011 are expected to be released on Thursday, April 28, 2011 before the open of the U.S. financial markets. The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the 2011 first quarter financial results and other business. The press release and the live...

2011-04-15 08:11:18

(Ivanhoe Newswire) --The current tactics hospitals are using to fight the spread of resistant bacteria in ICUs may not be working. A new multisite study led by the Mayo Clinic found that a commonly used strategy has not effectively helped to prevent the spread of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE). Thousands of Americans die from MRSA infections each year. Both MRSA and VRE are resistant to antibiotics and are difficult to treat if...

2011-04-14 12:28:44

NIH study evaluated 18 intensive care units WHAT: Expanded use of active surveillance for bacteria and of barrier precautions"”specifically, gloves and gowns"”did not reduce the transmission of two important antibiotic-resistant bacteria in hospital-based settings, according to a prospective, randomized clinical trial conducted in 18 intensive care units in the United States. Incomplete compliance by health care providers with recommended hand hygiene procedures and the use of...

2011-04-14 12:16:21

A new research study of the effect of a commonly used strategy to reduce the spread of antibiotic-resistant bacteria in hospital intensive care units (ICU) shows that the strategy had no significant effect. That's the surprising finding of a multisite study led by Mayo Clinic investigators. The bacteria -- methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE) -- are resistant to common antibiotics and harder to treat if patients become infected. The...

2011-04-06 06:00:00

SAN DIEGO, April 6, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) and Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the signing of an exclusive two-year co-promotion agreement to market DIFICID(TM) (fidaxomicin), in the United States. DIFICID is a novel antibiotic currently being reviewed for market approval by the FDA for the treatment of Clostridium difficile infection (CDI), which is also known as Clostridium difficile-associated diarrhea (CDAD)....


Latest Vancomycin Reference Libraries

0_4d46cc72a490344d44ba78359f528175
2011-04-26 21:07:20

Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...

0_71ad70ea6f0948a7e84406e760c7f5a4
2011-04-15 14:36:05

Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...

More Articles (2 articles) »
Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'kardia,' heart.
Related